INVO Fertility (IVF) Faces Nasdaq Compliance Issue Over Late Financial Filing
INVO Fertility Inc (IVF) has been notified by Nasdaq's Listing Qualifications Department regarding a compliance issue due to its failure to submit its Annual Report on Form 10-K for the fiscal year ending December 31, 2025. This delay is attributed to complex accounting matters, leading to a low GF Score™ of 29/100, indicating significant financial and profitability challenges. The company, which operates in the medical devices and instruments industry with its INVOcell device, has a market capitalization of $3.1 million and is currently not generating profits, signaling caution for investors.
APR 29·TipRanks▼
INVO Fertility receives Nasdaq notice regarding late Form 10-K filing
INVO Fertility (IVF) has received a notice from Nasdaq regarding its non-compliance with listing rules due to the late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The delay is attributed to complex accounting matters, including tax provision, warrant, and variable interest entity accounting. Nasdaq's notice does not immediately impact the company's stock listing.
JAN 31·TradingView▲
INVO Fertility Signs Multiple Material Agreements
INVO Fertility (IVF) has signed two financial agreements to enhance its liquidity. An institutional investor will exercise existing warrants for approximately $7.5 million, receiving new unregistered warrants. Additionally, the company has engaged Maxim Group as its exclusive lead warrant solicitation agent.
